Treatment of seizures in acute intermittent porphyria represents a therapeutic dilemma. Patients needing chronic therapy often experience acute porphyric attacks due to increased hepatic metabolism induced by the antiepileptic drugs themselves. Gabapentin is a new antiepileptic drug not appreciably metabolized by the liver in humans, and it appears to be safe and effective in the maintenance therapy of epilepsy in these patients. We report a patient affected by partial and generalized seizures in the course of acute intermittent porphyria, who was safely and successfully treated with gabapentin.
INTRODUCTION
Acute intermittent porphyria (AIP) is a rare inherited disease, which results from a partial deficiency of the enzyme porphobilinogen (PBG) deaminase, leading to hepatic overproduction and urinary excretion of heme precursors PBG and delta-aminolevulinic acid (ALA)'.
Porphyric acute attacks are typically precipitated by drugs1v2. Seizures, either partial or generalized, affect from 5% to 15% of patients3v4. Most antiepileptic drugs (AEDs) induce porphyric attacks, thus seizures in AIP are frequently undertreated with benzodiazepines (BDZs). Gabapentin (GBP) is a new AED that does not induce hepatic metabolism and is theoretically indicated for antiepileptic maintenance therapy in All? We report a patient safely and successfully treated with GBP
CASE REPORT
The patient is a 23-year-old woman who started antiepileptic therapy with phenobarbital (PB) at 100 mg/day after generalized status epilepticus since 19 years of age. Six months later she was admitted to our hospital after three generalized tonic-clonic seizures.
1059-l 31 l/98/05041 5 + 02 $12.00/O Routine blood and CFS examinations were normal, as well as a brain CT scan. An EEG showed bilateral posterior slow waves and brain MRI showed bilateral frontal gyriform lesions without enhancement. During her hospital stay the patient had recurrent partial and generalized seizures and phenytoin (PI-IT) was added to the therapy at 300 mg/day. Two weeks later the seizures disappeared, but she developed confusion, lethargy and tetraparesis. PHT intoxication was suspected and the antiepileptic therapy was modified to carbamazepine (CBZ) alone at 600 mg/day.
After an acute attack of abdominal pains and hallucinations, AIP was suspected and later confirmed by increased urinary ALA and PBG levels: ALA at 276 mg/dl (n.v. < 0.55), PBG at 4.87 mg/dl (n.v. < 0.15). Antiepileptic therapy was modified to valproic acid (VPA) at 400 mg/day. Until January 1996 she remained seizure-free and the EEG and brain MRI results normalized. Nevertheless, she presented recurrent acute attacks of abdominal pains with steady increased urinary levels of ALA and PBG. We started a therapy of GBP alone at 1200 mg/day. At present she is seizure-free with no more abdominal pains, although the menstrual cycle has started again after 1 year of pharmacological amenorrhea. The levels of urinary ALA and PBG reduced to 1.35 mg/dl and 1.9 mg/dl, respectively. The patient does not complain of any side-effects.
DISCUSSION
AIP is an autosomal dominant disease with low genetic penetration. Clinical symptoms usually appear with consumption of alcohol, drugs and hormones, fasting and other conditions'.
Acute attacks in AIP are typically precipitated by drugs, inducing activation of the hepatic cytochrome P450 system. All 'historical' AEDs are known to be porphyrogenic and cannot be used in chronic antiepileptic therapy in AIP5. Alternative treatment with BDZs is unsatisfactory, because first, they are less effective and second, tolerance develops with chronic therapy. However, BDZs remain the first choice in the treatment of seizures during acute attack8.
Bromides have been suggested for long-term treatment but, unfortunately, adverse effects on the skin, the gastroenteric and renal systems and on the CNS frequently occu?. GBP is a new AED structurally similar to the neurotransmitter gamma-aminobutyric acid. It is not metabolized in humans nor does it induce hepatic microsomal enzymes involved in drug metabolism7.
Our patient experienced acute porphyric attacks while treated with PHT, CBZ and VPA, although seizure-free. Moreover, during PB therapy seizures continued. There was a clear clinical improvement following GBP therapy and there was no doubt about its efficacy on seizures. Other epileptic patients have also been treated successfully with GBP8-'0. Recent in vitro tests demonstrated that GBP does not lead to an in-M. Zadra et a/ crease of porphyrins " , therefore, this drug can be used safely and/or successfully in the treatment of patients with AIP and epilepsy.
